Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft Rejection | 31 | 2022 | 149 | 3.350 |
Why?
|
Graft Survival | 28 | 2022 | 228 | 3.230 |
Why?
|
Hindlimb | 13 | 2017 | 57 | 3.190 |
Why?
|
Organ Transplantation | 9 | 2019 | 65 | 3.150 |
Why?
|
Immunosuppression | 14 | 2019 | 80 | 2.470 |
Why?
|
Mesenchymal Stem Cell Transplantation | 7 | 2017 | 75 | 2.360 |
Why?
|
Nanomedicine | 4 | 2020 | 17 | 2.230 |
Why?
|
Adipose Tissue | 4 | 2019 | 327 | 1.980 |
Why?
|
Reconstructive Surgical Procedures | 12 | 2018 | 190 | 1.890 |
Why?
|
Upper Extremity | 6 | 2017 | 52 | 1.870 |
Why?
|
Tacrolimus | 12 | 2022 | 44 | 1.860 |
Why?
|
Immunosuppressive Agents | 21 | 2022 | 167 | 1.780 |
Why?
|
Nerve Regeneration | 5 | 2018 | 40 | 1.550 |
Why?
|
Eye | 2 | 2019 | 15 | 1.420 |
Why?
|
Skin Transplantation | 6 | 2020 | 50 | 1.300 |
Why?
|
Transplantation Tolerance | 8 | 2019 | 14 | 1.250 |
Why?
|
Transplantation, Homologous | 24 | 2018 | 113 | 1.180 |
Why?
|
T-Lymphocytes, Regulatory | 7 | 2020 | 33 | 1.160 |
Why?
|
Animals | 48 | 2022 | 7299 | 1.100 |
Why?
|
Bone Marrow Transplantation | 6 | 2017 | 65 | 1.000 |
Why?
|
Rats | 23 | 2022 | 1604 | 0.890 |
Why?
|
Peripheral Nerves | 3 | 2018 | 58 | 0.890 |
Why?
|
Regenerative Medicine | 3 | 2019 | 187 | 0.830 |
Why?
|
Mesenchymal Stem Cells | 3 | 2021 | 161 | 0.810 |
Why?
|
Transplantation Immunology | 8 | 2020 | 27 | 0.810 |
Why?
|
Humans | 55 | 2023 | 29119 | 0.760 |
Why?
|
Rats, Inbred Lew | 10 | 2022 | 116 | 0.740 |
Why?
|
Transplantation | 2 | 2019 | 12 | 0.740 |
Why?
|
Adipogenesis | 1 | 2019 | 26 | 0.720 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2019 | 3 | 0.710 |
Why?
|
Anesthesia | 2 | 2017 | 65 | 0.690 |
Why?
|
Postoperative Complications | 8 | 2020 | 670 | 0.690 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2016 | 80 | 0.660 |
Why?
|
Transplantation Chimera | 6 | 2017 | 21 | 0.650 |
Why?
|
Tissue Engineering | 3 | 2019 | 608 | 0.630 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 83 | 0.610 |
Why?
|
Facial Transplantation | 3 | 2016 | 8 | 0.600 |
Why?
|
Perioperative Care | 1 | 2017 | 58 | 0.590 |
Why?
|
Postoperative Care | 4 | 2017 | 72 | 0.590 |
Why?
|
Chondroitin ABC Lyase | 1 | 2016 | 1 | 0.580 |
Why?
|
Rats, Inbred BN | 7 | 2022 | 32 | 0.570 |
Why?
|
Immunotherapy | 1 | 2017 | 69 | 0.570 |
Why?
|
Tissue Donors | 8 | 2023 | 167 | 0.530 |
Why?
|
Peroneal Nerve | 1 | 2015 | 14 | 0.530 |
Why?
|
Veins | 1 | 2015 | 29 | 0.520 |
Why?
|
Guided Tissue Regeneration | 1 | 2015 | 36 | 0.520 |
Why?
|
Spine | 2 | 2011 | 38 | 0.510 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 103 | 0.500 |
Why?
|
Hand Injuries | 3 | 2016 | 24 | 0.490 |
Why?
|
Program Development | 2 | 2011 | 85 | 0.470 |
Why?
|
Chimerism | 4 | 2023 | 4 | 0.460 |
Why?
|
Male | 34 | 2020 | 17815 | 0.450 |
Why?
|
Amputation, Traumatic | 2 | 2011 | 10 | 0.440 |
Why?
|
Immune Tolerance | 7 | 2020 | 67 | 0.430 |
Why?
|
Surgery Department, Hospital | 1 | 2011 | 7 | 0.410 |
Why?
|
Cells, Cultured | 6 | 2017 | 799 | 0.410 |
Why?
|
Adult Stem Cells | 1 | 2011 | 24 | 0.400 |
Why?
|
Patient Care Planning | 1 | 2012 | 53 | 0.400 |
Why?
|
Cell Separation | 1 | 2011 | 86 | 0.400 |
Why?
|
Patient Selection | 2 | 2012 | 257 | 0.390 |
Why?
|
Rats, Sprague-Dawley | 5 | 2019 | 747 | 0.350 |
Why?
|
Tissue and Organ Procurement | 2 | 2019 | 69 | 0.330 |
Why?
|
Blepharoplasty | 1 | 2008 | 2 | 0.330 |
Why?
|
Blinking | 1 | 2008 | 5 | 0.330 |
Why?
|
Dry Eye Syndromes | 1 | 2008 | 3 | 0.330 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2008 | 3 | 0.330 |
Why?
|
Pulmonary Alveoli | 3 | 2013 | 19 | 0.330 |
Why?
|
Transplantation, Autologous | 2 | 2019 | 78 | 0.310 |
Why?
|
Graft vs Host Disease | 3 | 2004 | 18 | 0.300 |
Why?
|
Feasibility Studies | 3 | 2020 | 263 | 0.300 |
Why?
|
Models, Animal | 6 | 2019 | 160 | 0.300 |
Why?
|
Macrophages | 2 | 2020 | 188 | 0.300 |
Why?
|
Time Factors | 7 | 2019 | 2001 | 0.290 |
Why?
|
Inflammation Mediators | 3 | 2020 | 101 | 0.290 |
Why?
|
Swine | 7 | 2022 | 201 | 0.270 |
Why?
|
Risk Assessment | 5 | 2019 | 1306 | 0.260 |
Why?
|
Patient Care Team | 4 | 2012 | 124 | 0.230 |
Why?
|
Tissue Transplantation | 3 | 2010 | 16 | 0.230 |
Why?
|
Immunomodulation | 4 | 2020 | 30 | 0.220 |
Why?
|
Surgical Flaps | 2 | 2015 | 69 | 0.220 |
Why?
|
Bone Marrow Cells | 3 | 2011 | 114 | 0.220 |
Why?
|
Cell Proliferation | 5 | 2017 | 573 | 0.220 |
Why?
|
Treatment Outcome | 8 | 2020 | 3100 | 0.220 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 1219 | 0.210 |
Why?
|
Organ Preservation | 2 | 2019 | 13 | 0.210 |
Why?
|
Cadaver | 2 | 2011 | 143 | 0.200 |
Why?
|
Neovascularization, Physiologic | 4 | 2018 | 106 | 0.200 |
Why?
|
Drug Carriers | 2 | 2019 | 16 | 0.190 |
Why?
|
Arm | 2 | 2012 | 31 | 0.190 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 532 | 0.190 |
Why?
|
Forelimb | 2 | 2019 | 4 | 0.190 |
Why?
|
Mice | 9 | 2020 | 2370 | 0.180 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2020 | 18 | 0.180 |
Why?
|
Cell-Derived Microparticles | 1 | 2019 | 5 | 0.180 |
Why?
|
Colloids | 1 | 2019 | 3 | 0.180 |
Why?
|
Prodrugs | 1 | 2019 | 13 | 0.180 |
Why?
|
Nanostructures | 1 | 2019 | 16 | 0.180 |
Why?
|
Skin | 3 | 2013 | 203 | 0.180 |
Why?
|
Drug Design | 1 | 2019 | 44 | 0.180 |
Why?
|
Ethics, Medical | 3 | 2012 | 16 | 0.180 |
Why?
|
Confidentiality | 1 | 2019 | 22 | 0.180 |
Why?
|
Extracellular Matrix | 2 | 2018 | 226 | 0.180 |
Why?
|
Hydrogen Sulfide | 1 | 2019 | 3 | 0.180 |
Why?
|
Skin Physiological Phenomena | 1 | 2019 | 7 | 0.170 |
Why?
|
Alloys | 1 | 2019 | 2 | 0.170 |
Why?
|
Tissue Scaffolds | 2 | 2019 | 386 | 0.170 |
Why?
|
Informed Consent | 1 | 2019 | 51 | 0.170 |
Why?
|
Absorbable Implants | 1 | 2019 | 24 | 0.170 |
Why?
|
Arteries | 1 | 2019 | 60 | 0.170 |
Why?
|
Oxygen | 1 | 2019 | 139 | 0.170 |
Why?
|
Bone Nails | 1 | 2019 | 28 | 0.170 |
Why?
|
Waiting Lists | 1 | 2018 | 30 | 0.170 |
Why?
|
Decanoates | 1 | 2018 | 2 | 0.170 |
Why?
|
Glycerol | 1 | 2018 | 5 | 0.170 |
Why?
|
Hyperbaric Oxygenation | 1 | 2018 | 5 | 0.170 |
Why?
|
Femoral Fractures | 1 | 2019 | 39 | 0.170 |
Why?
|
Cytokines | 4 | 2020 | 243 | 0.160 |
Why?
|
Mycophenolic Acid | 3 | 2019 | 28 | 0.160 |
Why?
|
Ischemia | 1 | 2019 | 92 | 0.160 |
Why?
|
Polymers | 1 | 2018 | 59 | 0.160 |
Why?
|
Models, Theoretical | 1 | 2019 | 126 | 0.160 |
Why?
|
Forearm | 3 | 2013 | 33 | 0.160 |
Why?
|
Optic Nerve Injuries | 1 | 2017 | 2 | 0.160 |
Why?
|
Interleukin-2 | 2 | 2015 | 33 | 0.160 |
Why?
|
Carotid Arteries | 1 | 2018 | 97 | 0.160 |
Why?
|
Reperfusion Injury | 1 | 2018 | 43 | 0.160 |
Why?
|
Blood Vessel Prosthesis | 1 | 2018 | 78 | 0.160 |
Why?
|
Retinal Ganglion Cells | 1 | 2017 | 16 | 0.160 |
Why?
|
Central Nervous System | 1 | 2017 | 29 | 0.160 |
Why?
|
Diffusion Tensor Imaging | 1 | 2017 | 29 | 0.150 |
Why?
|
Principal Component Analysis | 1 | 2017 | 60 | 0.150 |
Why?
|
Cell Survival | 3 | 2015 | 272 | 0.150 |
Why?
|
Pain | 1 | 2020 | 282 | 0.150 |
Why?
|
Blood Component Transfusion | 1 | 2017 | 10 | 0.150 |
Why?
|
Microspheres | 1 | 2017 | 37 | 0.150 |
Why?
|
Transducers | 1 | 2016 | 5 | 0.150 |
Why?
|
Magnetics | 1 | 2016 | 5 | 0.150 |
Why?
|
Nanoparticles | 1 | 2017 | 48 | 0.150 |
Why?
|
Schwann Cells | 1 | 2016 | 5 | 0.140 |
Why?
|
Image Enhancement | 1 | 2016 | 70 | 0.140 |
Why?
|
Lymphocyte Activation | 1 | 2017 | 80 | 0.140 |
Why?
|
Vascular Diseases | 1 | 2017 | 61 | 0.140 |
Why?
|
Female | 14 | 2020 | 18173 | 0.140 |
Why?
|
Inflammation | 1 | 2020 | 507 | 0.140 |
Why?
|
Islets of Langerhans Transplantation | 1 | 2016 | 40 | 0.140 |
Why?
|
Epigastric Arteries | 1 | 2015 | 1 | 0.140 |
Why?
|
Dissection | 1 | 2015 | 16 | 0.140 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2015 | 27 | 0.140 |
Why?
|
Acute Disease | 2 | 2019 | 239 | 0.140 |
Why?
|
Desensitization, Immunologic | 1 | 2015 | 3 | 0.140 |
Why?
|
Immunization | 1 | 2015 | 28 | 0.130 |
Why?
|
Glucose | 1 | 2016 | 163 | 0.130 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2015 | 25 | 0.130 |
Why?
|
Electrodiagnosis | 1 | 2015 | 35 | 0.130 |
Why?
|
Mandibular Neoplasms | 1 | 2015 | 6 | 0.130 |
Why?
|
Hydrogels | 3 | 2021 | 103 | 0.130 |
Why?
|
Thigh | 1 | 2015 | 39 | 0.130 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 246 | 0.130 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 97 | 0.130 |
Why?
|
Swine, Miniature | 3 | 2022 | 5 | 0.130 |
Why?
|
Burns | 1 | 2015 | 97 | 0.120 |
Why?
|
Bone Plates | 1 | 2015 | 68 | 0.120 |
Why?
|
Drug Delivery Systems | 3 | 2020 | 92 | 0.120 |
Why?
|
Lymphocyte Depletion | 2 | 2011 | 14 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2015 | 142 | 0.120 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 525 | 0.120 |
Why?
|
Wnt Proteins | 1 | 2013 | 18 | 0.120 |
Why?
|
Adult | 8 | 2018 | 8425 | 0.120 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 117 | 0.110 |
Why?
|
Bone Transplantation | 1 | 2013 | 47 | 0.110 |
Why?
|
Heart Transplantation | 1 | 2013 | 26 | 0.110 |
Why?
|
Drug Compounding | 1 | 2013 | 36 | 0.110 |
Why?
|
Adenocarcinoma | 1 | 2015 | 301 | 0.110 |
Why?
|
Receptors, CXCR4 | 1 | 2012 | 11 | 0.110 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2012 | 13 | 0.110 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2012 | 4 | 0.110 |
Why?
|
Karnofsky Performance Status | 1 | 2012 | 10 | 0.110 |
Why?
|
Esthetics | 1 | 2012 | 11 | 0.110 |
Why?
|
Personality | 1 | 2012 | 16 | 0.110 |
Why?
|
Facial Injuries | 1 | 2012 | 13 | 0.110 |
Why?
|
Langerhans Cells | 1 | 2011 | 1 | 0.110 |
Why?
|
Psychological Tests | 1 | 2012 | 33 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2012 | 23 | 0.110 |
Why?
|
Medical History Taking | 1 | 2012 | 32 | 0.100 |
Why?
|
Potassium Channels, Tandem Pore Domain | 1 | 2011 | 1 | 0.100 |
Why?
|
Public Relations | 1 | 2011 | 3 | 0.100 |
Why?
|
Hyperoxia | 1 | 2011 | 3 | 0.100 |
Why?
|
Rats, Inbred WF | 4 | 2004 | 8 | 0.100 |
Why?
|
Face | 1 | 2012 | 25 | 0.100 |
Why?
|
Edema | 1 | 2011 | 30 | 0.100 |
Why?
|
Chondroitinases and Chondroitin Lyases | 1 | 2011 | 1 | 0.100 |
Why?
|
Exanthema | 1 | 2011 | 21 | 0.100 |
Why?
|
Erythema | 1 | 2011 | 27 | 0.100 |
Why?
|
Wound Healing | 3 | 2019 | 182 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2011 | 61 | 0.100 |
Why?
|
Sirolimus | 2 | 2022 | 35 | 0.100 |
Why?
|
Cell Movement | 1 | 2012 | 161 | 0.100 |
Why?
|
Epithelial Cells | 1 | 2012 | 138 | 0.100 |
Why?
|
Motivation | 1 | 2012 | 102 | 0.100 |
Why?
|
Adaptation, Psychological | 1 | 2012 | 125 | 0.100 |
Why?
|
Glycosaminoglycans | 2 | 2018 | 20 | 0.100 |
Why?
|
Cell Culture Techniques | 1 | 2011 | 165 | 0.100 |
Why?
|
Social Support | 1 | 2012 | 163 | 0.100 |
Why?
|
Attitude to Health | 1 | 2012 | 148 | 0.090 |
Why?
|
Chronic Disease | 1 | 2011 | 370 | 0.090 |
Why?
|
Patient Compliance | 1 | 2012 | 208 | 0.090 |
Why?
|
Medication Adherence | 1 | 2012 | 144 | 0.090 |
Why?
|
Hyaluronic Acid | 2 | 2021 | 45 | 0.090 |
Why?
|
Rats, Inbred ACI | 3 | 2004 | 5 | 0.090 |
Why?
|
Health Status | 1 | 2012 | 368 | 0.090 |
Why?
|
Antibodies, Neoplasm | 1 | 2009 | 12 | 0.090 |
Why?
|
Risk Factors | 2 | 2019 | 3537 | 0.090 |
Why?
|
Breast Neoplasms | 1 | 2015 | 666 | 0.090 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 374 | 0.080 |
Why?
|
Cyclosporine | 3 | 2015 | 34 | 0.080 |
Why?
|
Muscle, Skeletal | 1 | 2013 | 494 | 0.080 |
Why?
|
United States | 3 | 2018 | 3632 | 0.080 |
Why?
|
Disease Models, Animal | 3 | 2020 | 980 | 0.080 |
Why?
|
Gene Expression | 2 | 2020 | 332 | 0.080 |
Why?
|
Middle Aged | 7 | 2018 | 10834 | 0.080 |
Why?
|
Recovery of Function | 1 | 2008 | 190 | 0.080 |
Why?
|
Mice, Inbred C57BL | 3 | 2016 | 711 | 0.080 |
Why?
|
Cell Line | 2 | 2011 | 450 | 0.080 |
Why?
|
Antibodies, Monoclonal | 1 | 2009 | 196 | 0.080 |
Why?
|
Surgery, Plastic | 1 | 2007 | 26 | 0.070 |
Why?
|
T-Lymphocytes | 3 | 2019 | 114 | 0.070 |
Why?
|
Collagen | 2 | 2018 | 217 | 0.070 |
Why?
|
Biocompatible Materials | 2 | 2019 | 210 | 0.070 |
Why?
|
Interprofessional Relations | 1 | 2007 | 47 | 0.070 |
Why?
|
Young Adult | 4 | 2018 | 2402 | 0.070 |
Why?
|
Epitopes | 2 | 2020 | 21 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2003 | 273 | 0.070 |
Why?
|
Quality of Life | 1 | 2012 | 816 | 0.070 |
Why?
|
Up-Regulation | 2 | 2020 | 183 | 0.070 |
Why?
|
Preoperative Care | 2 | 2019 | 110 | 0.070 |
Why?
|
Austria | 2 | 2018 | 3 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2018 | 2109 | 0.060 |
Why?
|
Hand | 3 | 2011 | 63 | 0.060 |
Why?
|
Lymph Node Excision | 1 | 2004 | 89 | 0.060 |
Why?
|
Histocompatibility Testing | 2 | 2016 | 15 | 0.060 |
Why?
|
Thymus Gland | 1 | 2023 | 15 | 0.060 |
Why?
|
Rats, Inbred F344 | 1 | 2003 | 125 | 0.060 |
Why?
|
Prognosis | 2 | 2018 | 1362 | 0.060 |
Why?
|
Chromatography, Liquid | 1 | 2022 | 42 | 0.050 |
Why?
|
Enzyme Activation | 2 | 2013 | 126 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 1 | 2023 | 95 | 0.050 |
Why?
|
Tandem Mass Spectrometry | 1 | 2022 | 57 | 0.050 |
Why?
|
Collagen Type I | 1 | 2021 | 39 | 0.050 |
Why?
|
Freund's Adjuvant | 1 | 2020 | 2 | 0.050 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2020 | 15 | 0.050 |
Why?
|
Endothelial Cells | 1 | 2021 | 179 | 0.050 |
Why?
|
Hydrocarbons, Cyclic | 1 | 2019 | 1 | 0.050 |
Why?
|
Half-Life | 1 | 2019 | 22 | 0.050 |
Why?
|
Dinoprostone | 1 | 2020 | 37 | 0.050 |
Why?
|
Fluorocarbons | 1 | 2019 | 18 | 0.050 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2019 | 66 | 0.050 |
Why?
|
Biological Transport | 1 | 2019 | 62 | 0.040 |
Why?
|
Cyclooxygenase 2 | 1 | 2020 | 50 | 0.040 |
Why?
|
Adjuvants, Immunologic | 1 | 2020 | 51 | 0.040 |
Why?
|
Transplantation Conditioning | 2 | 2013 | 11 | 0.040 |
Why?
|
Alginates | 1 | 2019 | 49 | 0.040 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 160 | 0.040 |
Why?
|
Vasa Vasorum | 1 | 2019 | 1 | 0.040 |
Why?
|
Corrosion | 1 | 2019 | 2 | 0.040 |
Why?
|
Titanium | 1 | 2019 | 9 | 0.040 |
Why?
|
Hyperplasia | 1 | 2019 | 38 | 0.040 |
Why?
|
Drug Implants | 1 | 2019 | 10 | 0.040 |
Why?
|
Regional Blood Flow | 1 | 2019 | 82 | 0.040 |
Why?
|
Knee | 1 | 2019 | 31 | 0.040 |
Why?
|
Tunica Intima | 1 | 2019 | 59 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2019 | 62 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2020 | 167 | 0.040 |
Why?
|
Replantation | 2 | 2011 | 9 | 0.040 |
Why?
|
Materials Testing | 1 | 2019 | 84 | 0.040 |
Why?
|
Femur | 1 | 2019 | 67 | 0.040 |
Why?
|
Random Allocation | 1 | 2019 | 213 | 0.040 |
Why?
|
Perfusion | 1 | 2018 | 64 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2018 | 37 | 0.040 |
Why?
|
Intermediate Filaments | 1 | 2018 | 1 | 0.040 |
Why?
|
GAP-43 Protein | 1 | 2018 | 6 | 0.040 |
Why?
|
Myelin Sheath | 1 | 2018 | 6 | 0.040 |
Why?
|
Penis | 1 | 2018 | 33 | 0.040 |
Why?
|
Tensile Strength | 1 | 2018 | 52 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2017 | 3112 | 0.040 |
Why?
|
Elastomers | 1 | 2017 | 1 | 0.040 |
Why?
|
Chemokine CCL5 | 2 | 2011 | 6 | 0.040 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2018 | 71 | 0.040 |
Why?
|
Uterus | 1 | 2018 | 73 | 0.040 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2018 | 74 | 0.040 |
Why?
|
Lung | 1 | 2019 | 233 | 0.040 |
Why?
|
Fetus | 1 | 2018 | 78 | 0.040 |
Why?
|
Adolescent | 2 | 2018 | 3254 | 0.040 |
Why?
|
Polyesters | 1 | 2017 | 72 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2019 | 637 | 0.040 |
Why?
|
Calcium | 1 | 2019 | 297 | 0.040 |
Why?
|
Computer-Aided Design | 1 | 2016 | 6 | 0.040 |
Why?
|
Animals, Inbred Strains | 1 | 2016 | 1 | 0.040 |
Why?
|
Equipment Failure Analysis | 1 | 2016 | 42 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 22 | 0.040 |
Why?
|
Weight-Bearing | 1 | 2016 | 40 | 0.040 |
Why?
|
Bone Regeneration | 1 | 2016 | 28 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2016 | 35 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2018 | 598 | 0.040 |
Why?
|
Equipment Design | 1 | 2016 | 167 | 0.040 |
Why?
|
Haplotypes | 1 | 2016 | 220 | 0.040 |
Why?
|
Survival Rate | 1 | 2018 | 795 | 0.040 |
Why?
|
Homeostasis | 1 | 2016 | 127 | 0.030 |
Why?
|
B-Lymphocytes | 2 | 2008 | 69 | 0.030 |
Why?
|
Plasmapheresis | 1 | 2015 | 9 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2015 | 21 | 0.030 |
Why?
|
HLA Antigens | 1 | 2015 | 35 | 0.030 |
Why?
|
Tumor Burden | 1 | 2015 | 60 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2015 | 76 | 0.030 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2015 | 4 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2015 | 48 | 0.030 |
Why?
|
Granzymes | 1 | 2015 | 5 | 0.030 |
Why?
|
Immune System | 1 | 2015 | 8 | 0.030 |
Why?
|
Infant | 1 | 2018 | 969 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2015 | 84 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2015 | 26 | 0.030 |
Why?
|
Child, Preschool | 1 | 2018 | 1167 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2015 | 199 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2016 | 726 | 0.030 |
Why?
|
Whole-Body Irradiation | 2 | 2004 | 48 | 0.030 |
Why?
|
Mice, Inbred C3H | 1 | 2013 | 23 | 0.030 |
Why?
|
Cell Transdifferentiation | 1 | 2013 | 6 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 11 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2015 | 436 | 0.030 |
Why?
|
Mice, Inbred DBA | 1 | 2013 | 36 | 0.030 |
Why?
|
Isoantigens | 1 | 2013 | 1 | 0.030 |
Why?
|
Aminoquinolines | 1 | 2013 | 16 | 0.030 |
Why?
|
Ultrasonography | 1 | 2015 | 345 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2013 | 37 | 0.030 |
Why?
|
Antilymphocyte Serum | 1 | 2013 | 17 | 0.030 |
Why?
|
beta Catenin | 1 | 2013 | 37 | 0.030 |
Why?
|
RNA Interference | 1 | 2013 | 76 | 0.030 |
Why?
|
Disease Progression | 1 | 2015 | 572 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2013 | 61 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2013 | 172 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 109 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2013 | 248 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2012 | 27 | 0.030 |
Why?
|
Tissue Inhibitor of Metalloproteinase-3 | 1 | 2012 | 1 | 0.030 |
Why?
|
Matrix Metalloproteinase 14 | 1 | 2012 | 1 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2012 | 8 | 0.030 |
Why?
|
Monitoring, Intraoperative | 1 | 2012 | 39 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 25 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2015 | 481 | 0.030 |
Why?
|
Child | 1 | 2018 | 2219 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2012 | 73 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2011 | 13 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2011 | 15 | 0.030 |
Why?
|
Antigens | 1 | 2011 | 31 | 0.030 |
Why?
|
Acute Lung Injury | 1 | 2012 | 30 | 0.030 |
Why?
|
Hemostasis, Surgical | 1 | 2011 | 13 | 0.030 |
Why?
|
Interleukin-8 | 1 | 2011 | 23 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2011 | 62 | 0.030 |
Why?
|
Cryopreservation | 1 | 2011 | 42 | 0.030 |
Why?
|
Extremities | 1 | 2011 | 48 | 0.030 |
Why?
|
Demography | 1 | 2011 | 104 | 0.030 |
Why?
|
Axons | 1 | 2011 | 24 | 0.030 |
Why?
|
Nerve Fibers | 1 | 2011 | 30 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 2011 | 47 | 0.030 |
Why?
|
Tendon Injuries | 1 | 2011 | 36 | 0.030 |
Why?
|
Sciatic Nerve | 1 | 2011 | 35 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2013 | 514 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2012 | 162 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2013 | 436 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2011 | 225 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2010 | 49 | 0.020 |
Why?
|
Biological Products | 1 | 2011 | 66 | 0.020 |
Why?
|
Prospective Studies | 1 | 2015 | 2021 | 0.020 |
Why?
|
Transplantation, Isogeneic | 1 | 2009 | 1 | 0.020 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2009 | 3 | 0.020 |
Why?
|
Vascular Surgical Procedures | 1 | 2010 | 91 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2011 | 519 | 0.020 |
Why?
|
Musculoskeletal Abnormalities | 1 | 2009 | 1 | 0.020 |
Why?
|
Spain | 1 | 2009 | 3 | 0.020 |
Why?
|
Functional Laterality | 1 | 2009 | 59 | 0.020 |
Why?
|
History, 21st Century | 1 | 2009 | 48 | 0.020 |
Why?
|
Amputation | 1 | 2009 | 37 | 0.020 |
Why?
|
Antigens, CD | 1 | 2008 | 100 | 0.020 |
Why?
|
Occupational Therapy | 1 | 2007 | 3 | 0.020 |
Why?
|
Psychiatry | 1 | 2007 | 12 | 0.020 |
Why?
|
Registries | 1 | 2007 | 278 | 0.020 |
Why?
|
Aged | 1 | 2018 | 9492 | 0.020 |
Why?
|
Chimera | 1 | 2004 | 8 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2004 | 23 | 0.020 |
Why?
|
Lymphocytes | 1 | 2004 | 53 | 0.020 |
Why?
|
Major Histocompatibility Complex | 1 | 2003 | 15 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2002 | 51 | 0.010 |
Why?
|
Public Opinion | 1 | 2002 | 17 | 0.010 |
Why?
|
Binding Sites | 1 | 2002 | 125 | 0.010 |
Why?
|
Heparin | 1 | 2002 | 75 | 0.010 |
Why?
|
Forecasting | 1 | 2002 | 133 | 0.010 |
Why?
|
Societies, Medical | 1 | 2002 | 149 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2002 | 239 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2002 | 162 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 298 | 0.010 |
Why?
|